What are the needs in oral antitumor therapy? An analysis of patients’ and practitioners’ preferences

Article / By

Patients and practitioners show a strong preference for oral antitumor therapy, particularly continuous regimens, over other treatment forms for hormone-receptor-positive, HER2-negative metastatic breast cancer. Both groups value the compatibility of oral therapies with daily life and prefer consultation intervals of four weeks. Effective patient education and management of side effects are crucial for maintaining quality of life during long-term treatment.

What are the needs in oral antitumor therapy? An analysis of patients’ and practitioners’ preferences Read More »

Artificial intelligence on breast cancer risk prediction

Article / By

This study aims to develop an Artificial Intelligence-based medical application for personalized breast cancer risk prediction using images from various modalities. The application will categorize patients into different risk groups, enabling tailored screening and preventive measures, and is designed for use in diverse medical facilities regardless of patients’ socio-economic backgrounds.

Artificial intelligence on breast cancer risk prediction Read More »

Single institution retrospective review of patients with metastatic hormone receptor positive breast cancer receiving first line therapy of CDK4/6 inhibitors.

Article / By

This study conducted a retrospective review of 41 patients with metastatic hormone receptor-positive breast cancer at the University of Louisville, finding that 63.4% received a combination of aromatase inhibitors and CDK4/6 inhibitors as first-line therapy. The results indicate that while the institution is largely compliant with treatment guidelines, there is a need to address barriers to optimal treatment adherence in Kentucky, where the use of CDK4/6 inhibitors is below the national average.

Single institution retrospective review of patients with metastatic hormone receptor positive breast cancer receiving first line therapy of CDK4/6 inhibitors. Read More »

Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.

Article / By

The study investigates the frequency of dose reductions (DR) of abemaciclib in patients with hormone receptor-positive, HER2-negative breast cancer, revealing that over half of the patients required DR due to adverse events. Those who reduced their dose experienced symptom improvement and remained on therapy longer, suggesting that a lower starting dose may enhance treatment adherence, particularly in older patients.

Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer. Read More »

Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications

Article / By

This review examines the incidental detection of pathogenic germline variants (PGVs) through liquid biopsy in patients with solid tumors, highlighting its prevalence and clinical implications. It discusses the challenges of managing this information, particularly regarding cancer predisposition and its impact on patient care and treatment strategies.

Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications Read More »

Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery

Article / By

The research discusses the role of breast cancer risk estimation models in identifying women eligible for genetic testing and risk-reducing surgeries related to hereditary breast and ovarian cancer (HBOC) syndrome. It highlights the distinction between high-risk and moderate-risk genes associated with breast cancer and compares various risk estimation models while noting their limitations.

Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery Read More »

Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

Article / By

The research aims to investigate whether a lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is as effective as the full dose in older patients (≥70 years) with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail. This study addresses the higher risk of adverse events associated with CDK4/6 inhibitors in older patients, as current practices often initiate treatment at lower doses without supporting evidence.

Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients Read More »

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Article / By

This review article examines the role of the PI3K pathway in breast cancer, highlighting its significance in predictive, preventive, and personalized medicine. It discusses the identification of predictive biomarkers, the potential for targeted therapies, and the need for further research to enhance treatment strategies and patient outcomes.

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway Read More »

Start typing and press enter to search

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm